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Abstract 
 Immunotherapy is an emergent form of cancer therapy that offers new and 
innovative techniques that work to enhance the body’s natural ability to defend 
itself against harm. This thesis seeks to explore the efficacy of vaccines that target 
dendritic cells as one particular form of immunotherapy. Vaccination has the 
potential to provide antigen (Ag) that is accessible to be processed by dendritic 
cells, deliver the antigen to the dendritic cells, encourage dendritic cell maturation 
and further promote the ability of dendritic cells to present antigen to effector cells 
to encourage a tumor antigen-specific immune response. There are several different 
elements in the process of achieving these ends including delivery of antigen to 
dendritic cells in-vivo or ex-vivo, antigen selection, antigen-carrier use, addition of 
adjuvants and the targeting of antigen to dendritic cells through soluble mediators. 
These different components of dendritic cell-directed vaccinations will be detailed 
and reviewed in order to understand the efficacy and immune-stimulating potential 
of possible vaccines. Additionally, through a series of experiments, we were able to 
determine that primed dendritic cells dramatically increased production of pro-
inflammatory cytokines after micro-particle endocytosis. These preliminary tests 
demonstrate that the tumor-Ag conjugated micro-particle matures dendritic cells to 
promote and activate an immune response. The results of the experiments that were 
performed and analysis of the various methods available for DC vaccination 
indicates that this method of cancer therapy has extensive potential and requires 
further testing to enhance efficacy and manufacturability of the vaccines.  
 
Introduction 
 In the United States, over a woman’s lifetime, she has a 1 in 3 chance of 
developing cancer. For men, this is a 1 in 2 chance [1]. Globally, 14 million people 
are diagnosed with cancer and eight million people die from the disease each 
year[2]. Despite the great strides that have been made in cancer research, 
treatment, and long-term therapies, many patients still continue to develop 
progressive, metastatic disease. At this point in time there are several different 
methods of trying to combat and eliminate cancer cells in the body. Traditional 
therapies include chemotherapy, radiotherapy, and surgical removal of tumors, but 
a new and promising line of cancer therapies has emerged from the discipline of 
immunotherapy.  Immunotherapy seeks to harness the power of the immune 
system and direct it to fight tumor cells. These therapies are often used concurrently 
with traditional methods of treatment in order to maximize a patient’s response to 
the therapy. These therapies are designed to elicit an immune response through 
targeting specific antigens in the body (such as a tumor antigen), priming immune 
cells to attack tumor cells selectively, trafficking appropriate immune cells to tumor 
sites and neutralizing the immunosuppressive environment around the tumor cell 
[3].  
One type of immunotherapeutic approach involves vaccination. Cancer 
vaccines are intended to encourage the body’s immune system to respond to 
antigens that indicate the presence of an abnormal or cancerous cell. The immune 
system recognizes a wide variety of antigens, which can be derived from exogenous 
or endogenously expressed proteins. [4]. For example, antigens generated from 
exogenous proteins are typically derived from pathogens including bacteria or 
viruses. In contrast, endogenous proteins originate from within the body and 
include normal self-proteins and those produced by abnormal or cancerous cells [4]. 
The goal of tumor-specific vaccination is to use antigens to activate cytotoxic T cells 
capable of recognizing and responding to cancer-specific proteins. A promising 
method of initiating this activation is known as dendritic cell vaccination. Dendritic 
cells are a type of immune cell generated from the bone marrow that are critical in 
initiating an immune response [3]. Dendritic cells do this by collecting antigens, 
processing them and presenting them on their surface. This ability places them in a 
category of cells known as antigen-presenting cells (APCs) [3]. In the vaccination 
approach, dendritic cells are loaded with adjuvants that will cause maturation of the 
cell as well as tumor antigens that will be presented by the dendritic cell to other 
immune cells that will then locate and fight tumor-specific cells [5]. There have been 
various studies using this approach to combat a variety of cancer types. These 
studies will be reviewed and evaluated for their effectiveness in eliciting an immune 
response through dendritic cell vaccination.  In addition, we will discuss our studies 
that used a tumor-specific antigen (SPAS-1) along with adjuvants in a dendritic cell 
vaccination (DC vaccination) model in order to explore one possible way in which 
DC vaccination could enhance the tumor-specific immune response. 
 
 
 
 
Innate Immune System 
 The immune system is an integral part of the body’s survival mechanism that 
evolved as the result of perpetual exposure to pathogens, organisms and foreign 
molecules. The immune system functions as an interconnected network of organs, 
cells and molecules that work to protect and repair the body.  This system of 
defense is divided into two sections, innate immunity and adaptive immunity.  Both 
of these systems operate in unique ways, but it is in their combined efforts that the 
body is able to defend its self from viruses, diseases, parasites and even internal 
threats such as cancer.  
 The innate immune system has developed from millions of years of evolution 
and can be viewed as the elemental defense system. Innate immunity is the first 
system to react once a pathogen has been detected in the body [6]. A pathogen can 
be defined as any organism or agent that can cause disease. The innate immune 
system is not pathogen specific; instead, it recognizes molecules that are found in 
many pathogens, but are not found in the body [7].  These molecules are also known 
as pathogen associated molecular patterns (PAMPs). Some of these stimulants 
include molecules on the cell surface of the pathogen such as lipopolysaccharide 
(LPS), teichoic acid, or bacterial flagella. PAMPs can also include short DNA 
sequences such as CpG, which is an un-methylated repetition of the bases guanine 
and cytosine [7]. Together PAMPs provoke the initial innate immune response. 
 There are several different cell types that function within the innate immune 
system. One of these cells is the macrophage. Macrophages are derived from blood-
born monocytes. These cells are able to distinguish between “foreign” and “self” 
molecules. This ability is crucial to protecting the body from attacking itself and thus 
deterring autoimmune responses. Macrophages also have receptors for antibodies 
and complement, which will be discussed in a further section. These receptors allow 
for the cell to enhance its phagocytic abilities [6]. Through phagocytosis, 
macrophages  (and other phagocytic cells) can uptake, break down and destroy 
pathogens. Eosinophils are another kind of immune cell. These cells function 
primarily to protect the body from parasitic infections. These cells are not 
phagocytic and rely on the release of cytokines and cationic proteins to kill foreign 
invaders [6, 8] .   
 Natural Killer cells (NKs) are another group of cells within the innate 
immune system that protect the body from pathogens and normal (self)-cells that 
have been infected. NKs have many of the same morphological features of 
lymphocytes, however they do not possess specific antigen receptors. Instead NKs 
recognize abnormal or pathogenic cells through two different pathways.  The first 
pathway is through the use of immunoglobulin receptors (FcR). NKs can use these 
receptors to bind to targets coated with antibodies. After binding to a target 
pathogen, the NK is able to attack using antibody-dependent cellular cytotoxicity [8]. 
This method induces the cell to terminate itself via apoptosis. The second pathway 
through which NK cells function in the innate immune system is through the 
monitoring of MHC class I levels. These MHC proteins are expressed on almost 
vertebrate cells. When an NK detects high levels of MHC proteins, it will not attack 
the cell. However, when the NK observes low levels of MHC class I proteins, it is able 
to selectively kill cells such as virally infected cells as well as cancer cells [7]. NKs 
are extremely important to preventing viral replication as well as the expansion of 
cancer cells.  
 Another cell type within the immune system that plays an important role as a 
bridge between the innate and acquired immune system is the dendritic cell.  
Dendritic cells are potent antigen-presenting cells that will be discussed in greater 
detail in following sections. Dendritic cells are covered with a variety of receptors 
including lipopolysaccharide receptors, mannose receptors as well as toll-like 
receptors and several others. These receptors allow the cells to recognize antigens, 
endogenous danger signals (such as those secreted by virally infected cells, or heat-
shock proteins resulting from necrotic cells) [6].   
 One of the first steps to occur within the innate immune system is the release 
of cytokines from macrophages in what is known as an inflammatory response. 
Macrophages are long-living immune cells that “patrol” tissues in the body and 
engulf foreign pathogens through phagocytosis [7].  Cytokines are a group of soluble 
proteins that help regulate cellular activity within the body, particularly the immune 
system [6]. Once a macrophage has taken up a pathogen it becomes activated and 
releases a series of cytokines including granulocyte (G-CSF) and granulocyte-
macrophage colony simulating factors (GM-CSF). These cytokines stimulate the 
bone marrow to differentiate myeloid precursors into neutrophils, which are 
subsequently released by the millions into the blood stream [8]. These neutrophils 
are then recruited to the site of the invader and are able to uptake and kill the 
pathogen or microorganism.  
 The complement system is another key part of the innate immune system.  
The complement system is made up of a series of 20 proteins that are produced by 
the liver and that circulate through the blood and the extracellular fluid. These 
proteins are activated by both antibodies produced by B cells as well as by PAMPs to 
attack the pathogens through lysis or by making them more susceptible to 
phagocytosis [7].  The proteins within the complement system are activated in a 
“cascade sequence” that has a self-amplifying effect, which reinforce its rapid and 
destructive abilities. The complement proteins have limited pattern recognition 
abilities allowing them to primarily target invading pathogens, however some cells, 
such as resident microbes within the body can also be targeted by these proteins. 
This sequence must promptly be deactivated in order to prevent the complement 
proteins from attacking self-cells [7].  
 Aside from complement proteins, there are several other non-cellular 
elements that function within the innate immune system. Many of these factors 
serve as mediators, messengers and triggers that promote inflammatory responses, 
complement cascade activation as well as immune cell activation and recruitment. 
One such group of molecules is known as acute-phase proteins. The levels of these 
proteins increase in response to infection and inflammation and they serve to 
encourage tissue regeneration and promote resistance to infectious agents [6].  
 Cytokines are another group of soluble factors; they serve, for the most part, 
as messengers both within the immune system and between the immune system 
and other systems within the body [9]. Besides functioning as messengers, some 
cytokines also have the ability to function directly within defense responses. Some 
of these functional cytokines play important roles in mediating tumor resistance 
and are increasingly being used as “therapeutic agents” in combination with 
glycoproteins such as interferons.  
 Another group of molecules closely involved in communication is the group 
known as adhesion molecules. These molecules are bound to the surface of immune 
cells and facilitate information transmission between cells. These molecules are 
critical in guiding movement of cells, promoting phagocytosis and regulating cellular 
cytotoxicity [8]. These adhesion molecules, once attached to the cell surface can 
encourage cell activation, cytokine production and promote the up-regulation of 
surface receptors.  
 The functions of the adhesion molecules, like those of cytokines, complement 
and acute-phase proteins are critical to enabling the immune system to recruit cells 
to sites of inflammation, defend against malignant or infected cells, “warn” other 
cells of the threat as well as promote a regenerative environment so that the body 
can begin to heal itself.  
 Together, innate immune cells and non-cellular immune factors work 
collectively to provide the first rapid response for defense against foreign pathogens 
and malignant cells that are detrimental to the host. Innate immunity non-
discriminately safeguards the body. Its non-pathogen-specific design allows it to act 
quickly and broadly and defend against a wide array of threats. While the processes 
under innate immunity can be advantageous and useful in immune defense, in order 
to create long-lasting and pathogen-specific responses, there must be collaboration 
with the adaptive immune system. This collusion transpires largely through the 
intermediary position of dendritic cells, which facilitate the cooperation of both 
parts of the immune system.  
 
Adaptive Immune System 
 While the innate immune system plays an important role as the first line of 
defense against pathogens, the adaptive immune system, also known as the 
acquired immune system, works to produce highly developed and targeted 
responses. The innate immune system responds to the general presence of 
pathogens, on the other hand, the adaptive immune system mounts responses to 
specific pathogens encountered in the body. The adaptive immune system is 
engaged only when the innate immune system detects the presence of PAMPs and 
foreign Ag. This allows the immune system to develop specific responses only when 
there is a genuine threat and not when there is merely a benign presence [9].  
 The adaptive immune system functions primarily through white blood cells 
known as lymphocytes. Lymphocytes, which can be divided into two separate cell 
types - B cells and T cells, develop within the bone marrow through processes 
guided by stromal cells and cytokines [6]. B cells and T cells have antigen-specific 
receptors, which empower them to produce their own unique immune responses.  B 
cells produce as antibody responses and T cells deliver cell-mediated immune 
responses [9].  Following the presentation of antigen (Ag) to its respective antigen-
specific lymphocyte, the T and B cells are primed, activated and differentiated into a 
variety of effector cells with unique functions [8]. Together, B and T cells generate 
pathogen-specific responses that allow for targeted, specific and long-lasting 
defenses.  
 Antibody responses constitute one crucial component of the adaptive and 
innate immune system. These responses are carried out by activated B-cells. In this 
mechanism, B cells are signaled by other immune cells to secrete antibodies, which 
belong to a group of glycoproteins known as immunoglobulins [9]. Antibodies are 
composed of two main parts: two identical heavy chains, two identical light chains 
[6]. At the N-terminal end of Ab, there are sites to which antigens can bind. 
Antibodies have highly variable antigen-binding sites, which allows highly specific 
recognition of unique antigens. This enables the antibody to “recognize” the antigen. 
Antibodies serve several functions. They are able to activate complement, encourage 
phagocytosis of bacteria, and bind to tumors and infected cells, which allows 
effector and killer immune cells to target and attack the malignant cell [8]. Aside 
from the functions of antibodies that have been released into the body by the 
mature B cells, antibodies also play a key role in immature B cells. In the early stages 
of B-cell development, antibodies are imbedded in the cell surface. Here, early 
antibodies function primarily as receptor proteins that allow B-cells to capture 
antigen and subsequently process it to present it via MHC class II surface molecules 
to T-cells [8]. This process is similar to that which takes place in several other 
immune cells known as Antigen Presenting Cells (APCs). Through these unique 
functions of antibodies, B cells are able to contribute to both innate and adaptive 
immune responses.  
 Once an antigen is expressed on the cell surface of a B-cell, it can be 
presented to a particular subset of antigen-specific T cells.  Just like B cells recognize 
specific antigen via embedded surface antibody receptors, T cells carry unique 
receptors designed to recognize distinct Ag presented by the B cell receptor. Once a 
B-cell and a T-cell have combined recognition of the antigen, the T cell begins to 
produce cytokines that promotes B-cell maturation, subsequently leading to the 
antibody release previously described [6, 9].  
 While T-cells play a role in B-cell maturation/activation, they also serve a 
variety of other functions within the adaptive immune system. Naïve T cells are, for 
the most part, contained within the lymphoid tissue such as the spleen and lymph 
nodes. Within the lymphatic system, the T cell will come in contact with an APC that 
is presenting its antigen on the cell surface. This process is largely executed by 
dendritic cells (DCs) that actively present antigen in the lymphoid tissues via MHC 
class I or class II molecules. Other APCs include B cells and macrophages, each of 
which promotes the T cell to develop and mature in unique ways. Once the T cell 
interacts with the antigen, the T cell undergoes an activation period [8]. 
 There are several different subclasses of T lymphocytes, which are 
comprised largely of CD4+ and CD8+ cells.  In their origins, T cells express both CD4 
and CD8 co-receptors. During maturation in the thymus however, T lymphocytes 
lose expression of one of the two co-receptors and consequently become selective to 
the pathway of antigen recognition. These two emergent subclasses of T cells will 
recognize antigen through different pathways and develop into effector cells with 
unique abilities and functions [9, 10].  CD4 T cells only recognize antigen presented 
via the MHC class II pathway, whereas CD8 T cells are uniquely able to respond to 
antigen presented through MHC class I molecules [8]. MHC class I molecules 
primarily function alert the immune system to the presence of virally infected cells 
by presenting peptide fragments derived from self-proteins [11].  MHC class II 
molecules, on the other hand, present antigen derived from exogenous sources [12]. 
  In addition to stimulation via the MHC complex, T cells require co-
stimulatory molecules to enable them to fully mature. TCR stimulation in the 
absence of the appropriate co-stimulatory signals usually results in anergy or 
apoptosis of the T lymphocyte. Dendritic cells (DCs) are one of the most effective 
cells at promoting T cell activation as they are very efficient at Ag processing and 
presentation and they express high levels of co-stimulatory molecules B7 and CD40. 
[8].  Dendritic cells play a unique role within both the innate and adaptive immune 
system and will be discussed in greater detail in the following section.  
 The innate immune system and the adaptive immune system, while utilizing 
decidedly distinct methods of defending the body from harm, are only effective 
through the inherent cooperation of both systems. These systems rely on 
intercellular communication, cellular and non-cellular components and on complex, 
interdependent pathways that work to defend the body against pathogens of all 
sorts and, critical to this discussion, against host-borne malignancies such as cancer. 
The immune system has the ability to defend itself against perpetual exposure to 
foreign elements. The potential for cancer-defense is self evident in the potent and 
effective design of the immune system. By understanding how and why the immune 
system works, it is possible to harness its extant abilities and direct them towards 
cancer cells. In the following section the importance and use of dendritic cells in 
mediating the immune system will be illustrated.  
 
Dendritic Cells 
 For decades the extent to which the immune system was able to uptake and 
respond to external stimuli was not fully understood by immunologists and 
biologists. Macrophages were viewed as the primary actors in the innate immune 
system, however there was little evidence showing that macrophages linked the 
innate to the adaptive immune system [13]. In 1973 Ralph Steinman’s discovery of 
dendritic cells and subsequent research into their role in adaptive immunity forever 
changed the understanding of the immune system and how it functions as a unit 
rather than two separate entities. This discovery, which earned Steinman the 2011 
Nobel Prize in Medicine of Physiology, is critical not only to understanding the 
immune system, but also how to manipulate it for medical advancements [14]. 
  Dendritic cells (DCs) serve a unique role within the immune system as they 
function as a critical link between the innate and the adaptive immune system. DCs 
are the most potent of the professional antigen presenting cells (APCs), which 
include DCs, macrophages and certain B cells. In order to understand the extent to 
which DCs function as a critical bridge within the immune system, it is important to 
first understand DC biology, diversity and role in activating adaptive immune 
responses.  
 Dendritic cells are a part of the body’s innate immune system. DCs are 
derived in the bone from bone marrow-derived precursors and subsequently leave 
through the blood stream as immature DCs and seed themselves into peripheral 
tissues or directly in the lymph nodes [3, 15].  Immature DCs present in peripheral 
blood and tissues are able to capture and uptake antigen (Ag) through several 
integral processes (e.g. endocytosis and phagocytosis) [3, 14, 16]. Once a DC has 
taken up and processed the antigen, it then undergoes maturation through the 
direction of several cytokines [16]. In the maturation stage, the DC decreases its 
ability to uptake antigens, and up-regulates its surface expression of MHC Class I 
and MHC class II molecules, increasing the DC’s capacity to express the processed 
antigen.  Additionally, the DC up-regulates its expression of the chemokine receptor 
CCR7, which allows it DC to migrate to a location where it can present antigen to T-
cells [14].  
 After the uptake of Ag, the tissue-resident DC migrates to the draining lymph 
nodes through afferent lymph vessel, which allow entry of cells into the lymph node 
through all parts of its periphery [3]. Concurrently, the DCs process the Ag into 
peptides, which are fragments of proteins, that then bind to and are presented on 
the DC surface by MHC class I and MHC class II molecules. Once a DC has processed 
the Ag and presented the ensuing peptide on the MHC complex, this complex is then 
presented to naïve T cells in the lymph nodes and lymphoid tissues [14]. Naïve T 
cells bind to the MHC-peptide complex and co-stimulatory molecules present on the 
DC surface (e.g. CD80, CD86 and CD40), resulting in the activation and 
differentiation of the T-cells. Typically, extracellular antigens such as bacteria, 
parasites and toxins are presented via the MHC class II molecules and are presented 
to CD4+ T cells. DCs present intracellular antigens including viral proteins and 
tumor antigens expressed on MHC class I molecules to CD8+ T cells [14]. The 
process through which DCs are able to take up exogenous proteins and present 
them to CD8 T cells is known as cross-presentation.  This aspect of DC antigen 
presentation is critical to the understanding of the adaptive immune system and it’s 
manipulation due to the fact that DCs are the only APCs that are able to present 
extracellular antigens to CD8+ T-cells.   
 
Figure 1. When immature DC come into contact with the correct combination of 
antigen and maturation stimuli, the proceed to their mature, differentiated form and 
are then able to process and present antigen via cross-presentation to T cells. This 
figure was adapted from source #[17].  
 
 The location of uptake of Ag can lead to distinct responses by T-cells [3]. 
Lymph-node resident DCs acquire their antigen directly from the lymph and present 
their peptides to naïve CD4+ T cells. In the presence of the appropriate stimuli (co-
stimulation, etc) presentation of peptides results in T cell priming, and the 
production of cytokines such as interleukin 2 (IL-2), which subsequently promotes 
T cell proliferation and expansion. This process works conjunctively with the tissue-
resident DCs. The DCs that capture antigen in the peripheral tissues and 
subsequently migrate to the lymph nodes to present their peptide already activated 
CD4+ T cells, which, in turn, promotes the formation of effector T cells, particularly 
CD4+ T helper cells [16, 18].  
 
T-Cell Differentiation 
 The presentation of antigen to naïve T cells and their subsequent activation 
is dependent upon several key chemical pathways and co-stimulation by the DCs. 
Additionally, depending on the pathway, and the DC subset involved in the 
activation process, T cells can differentiate into a variety of effector cells with 
unique functions and abilities. As previously stated, DC up-regulate their co-
stimulatory surface molecules, which interact with corresponding molecules on the 
T cell surface to trigger its activation [16]. DCs also secrete cytokines, which 
function to direct T cell differentiation.  Naïve CD4+ T cells can differentiate into T 
helper 1 cells (Th1), T helper 2 cells (Th2), T helper 17 cells (Th17) or T follicular 
helper cells (Tfh) (and regulatory T cells). Th1 cells function as effector cells within 
cell-mediate immune system that combats intracellular viruses and bacteria. These 
cells also secrete cytokines which promote macrophage activation and cytotoxic T 
cell production [19]. The Th1 subset of T cells secrete pro-inflammatory cytokines 
that help to recruit cells such as neutrophils and macrophages to a site of 
inflammation [20].Th2 cells are another variety of CD4+ effector T cell. Like Th1, 
Th2 cells encourage production of B cells and macrophage activation. Additionally, 
these cells have been associated with eosinophil and mast cell activation [21]. 
Finally, Tfh cells are critical in the formation of germinal centers, which are sites 
located within the lymphatic system that promote B cell maturation and their 
subsequent differentiation into plasma cells and memory B cells [22]. Naïve CD8 + 
cells initially become effector cytotoxic T lymphocytes (CTLs) and then can further 
differentiate into various subsets of memory cells, including central and effector 
memory cells [3]. Each of these cells play a crucial role in immune responses and the 
ability to shape how T cells differentiate is key to creating a successful immune 
response against cancer cells.  
 
Dendritic Cell Subsets 
 There are several different subsets of DCs and each subset has its own 
unique function within the immune system. Human DC populations can be broken 
down into two major subsets, plasmacytoid dendritic cells (pDCs) and myeloid 
dendritic cells (mDCs), also known as conventional dendritic cells (cDCs) [23].  
  Plasmacytoid DCs are distinguished by their expression of the surface 
molecule CD303+ and function primarily through the innate immune system. This 
subset of DC is primarily found in the blood, thymus, bone marrow and lymph nodes 
as well as other lymphoid organs. pDCs primary functions are to promote anti-viral 
and anti-microbial innate immunity [14]. They do this primarily through the 
secretion of type I interferons (IFNs) [23], which are a class of cytokine that can 
initiate a rapid CD8+ T cell response and promote the “immunogenic maturation” of 
other DC subsets [3]. pDCs are also capable of directing the transformation of 
activated B cells into plasma cells [3].  There is some evidence that pDCs can 
infiltrate tumors, however, there is still debate as to whether they play an anti-
tumor role or whether they can promote tumor growth [14].   
 While the pDCs demonstrate limited utility in combatting tumors and tumor 
growth, the mDCs show promise for use in cancer therapy due to the fact that they 
have strong capabilities at processing and presenting antigen and thus activating 
strong antigen-specific T cell responses. mDCs differentiate from myeloid 
progenitors into several further subgroups.  Some of these subgroups include 
lymphoid tissue resident DCs, which include CD8+ DCs and CD8- DCs as well as 
migratory DCs, which are the CD103+ DCs, CD11b+ DCs, epidermal Langerhans cells 
and dermal interstitial cells [3, 23].  The lymphoid-tissue resident DCs arise from 
precursors within the lymphatic system and are immature until stimulated by 
antigen within the lymphoid organs. The migratory DCs differ in that they are 
mature by the time that they reach the lymph [23].  
 One of the most important types of DCs in promoting an adaptive immune 
response are the lymphoid tissue resident CD8+ DCs. This DC subset produces 
particularly high levels of IL-12p70. IL-12p70 is an interleukin that stimulates the 
production of interferon gamma (IFN-y) and tumor necrosis factor alpha (TNF-a), 
which facilitates the differentiation of naïve CD4+ T cells into Th1 cells [24, 25]. 
Additionally, CD8+ DCs are highly competent at capturing and presenting exogenous 
Ag via the MHC class I pathway to CD8+ T cells through cross-presentation [23]. 
These DCs are also proficient at capturing and processing dead or dying cells, which 
makes them valuable in anti-tumor immunity efforts. By being able to take up and 
process tumor cells combined with their strong ability to cross present, CD8+ DCs 
are critical to initiating antigen specific T-cell responses against tumors.  
 While CD8+ DCs are highly capable of cross presentation through the MHC 
class I pathway, CD8- DCs and the migratory DCs: CD11b+ DCs and Langerhans’ 
cells, play key roles in driving B cell responses and are more effective at presenting 
antigen through MHC class II surface molecules. CD8- DCs and Langerhans’ cells are 
superior mediators at antigen presentation via the MHC class II pathway [23].This 
pathway, as discussed earlier, typically functions to active CD4 T cells.  This is 
evident in the ability of the migratory DCs to promote differentiation of naïve CD4+ 
T cells into Tfh-like cells [3]. These differentiated T cells are highly valuable in 
promoting lasting immunity through the production of memory B cells. Another key 
function of migratory DCs is their ability to shuttle Ag from where it was taken up to 
a lymph node where it can “give” the Ag to a CD8a+ DCs, which are able to cross-
present with CD8+ T Cells [23].  The ability of the migratory DCs to donate their 
antigen for presentation by other DCs combined with their own ability to cross 
present Ag, allows for activation of both CD4+ and CD8+ T cells.  
 Maturation is a critical factor in DC directed immunity. Immature DCs are 
effective at taking up Ag, however, antigen presentation by an immature DC is more 
likely to induce immune tolerance to the Ag. Mature DCs, on the other hand, are 
capable of inducing immunity through their particular ability to stimulate an 
antigen specific T cell response coupled with their expression of potent co-
stimulatory signals. DCs mature in response to exposure to “pathogens and their bi-
products” [23]. Pathogens have certain unique signifiers that, combined with the 
presence of an antigen, alert the DC to a threat and encourage the DC to mature in 
order to be able to stage an immune response.  Some of these signifiers come in the 
form of pathogen-associated molecular patterns (PAMPs) and endogenous ligands. 
These pathogen bi-products are recognized by DCs through the Toll-like receptors 
(TLRs) on the cell surface.  This leads to B7.1, B7.2 expression, IL-12 production, 
and increased MHC expression on their surface, all of which help boost their ability 
to stimulate naïve T cells in the lymph nodes. The ability to activate and promote 
maturation and differentiation of DCs through adjuvants will be a critical concept in 
the coming sections as this permits experimental manipulation of DCs and the 
adaptive immune responses that they initiate.  
 Dendritic cells are powerful players within the immune system. They are 
able to bridge the innate and adaptive immune systems to drive robust B and T cell 
responses; it is through this dynamic that the immune system has the capability to 
defend itself not only against foreign pathogens, but also from cancers originating 
from within the body. The next sections of this article seek to evaluate two methods 
of DC vaccination capable of enabling immune responses that fight against cancers: 
ex-vivo (in-vitro) and in-vivo vaccinations.  
 
Ex-vivo DC Vaccination 
 The immune system is capable of fighting a range of pathogens including 
parasites, bacteria, and viruses. Through the systems in place designed to target and 
destroy invading elements, there is the potential for the immune system to be able 
to fight self-derived maladies, such as cancer. While the immune system can 
eliminate early neoplastic cells that arise under normal conditions, once the cells 
begin to multiply and mutate too quickly the immune system no longer has the 
innate capacity to control the massing cells. In the beginning of a tumor growth, 
there is a point at which the immune system wins out over the growing cells and is 
able to eliminate them. In a second phase of tumor progression, there is a 
equilibrium between the multiplication of the neoplastic cells and the rate at which 
the immune system can destroy them. For these cells to progress to the point of 
becoming a tumor, the immune system loses its control in a process known as tumor 
“escape” [26].  One possible way of activating the immune system to combat cancer 
cells once they reach the point of escape is by targeting dendritic cells through 
vaccination.  
 Through vaccination, dendritic cells could be activated to help induce an 
immune response that directly targets cancer cells. There are two broad categories 
of DC-based vaccines: ex vivo and in vivo. Currently, Provenge (sipuleucel-t), is the 
only DC-based vaccine that has been approved by the FDA. Provenge is an ex-vivo 
generated vaccine that is used for patients with metastatic prostate cancer. The use 
of this dc-based vaccine has demonstrated a 4-month median increase in survival 
compared to patients’ treated with a placebo vaccine [14]. This success 
demonstrates that the future of DC-vaccinations is conceivable and that through 
proper research and development, full-scale vaccinations covering an array of 
cancers could someday be viable treatment options. In the following sections, ex-
vivo and in-vivo DC vaccinations will be discussed and evaluated for their efficacy, 
their pragmatism, and their potential for inducing long-term cancer immunity.  
 Ex-vivo dendritic cell vaccinations are constructed by culturing 
haematopoietic progenitor cells or monocytes with antigen and cytokines that are 
able to induce DC maturation and increase their capacity to elicit tumor specific 
immune responses [3]. These progenitor cells and monocytes are typically obtained 
directly from the patient and as such, the preparation of ex-vivo vaccinations can be 
labor intensive and expensive. On the other hand, the vaccinations can be precisely 
tailored to the individual’s needs and unique situation. As previously mentioned, 
there is only one FDA approved DC-based vaccine. There are several possible 
explanations for why DC vaccinations have largely been thus far futile. Foremost, the 
tumor microenvironment (TME) is highly successful at evading immune detection, 
misdirecting immune cells, and inducing anergy among cells that are potentially 
threatening to the tumor. Furthermore, to properly optimize dendritic cells to 
enhance effective response, there are many different factors that must be taken into 
consideration including: which kind of stimuli are used to activate the DC, which 
kind of antigen to present and in what form, where and how many primed DCs 
should be administered, how often and various other deliberations [14]. It is crucial 
to understand these various elements of creating the vaccine in order to generate a 
successful vaccine that is able to induce the immune system to directly target the 
tumor and bypass the TME.  
 
Figure 2. General Ex-Vivo Dendritic Cell Vaccination Strategy [27]: Ex-vivo derived 
DC vaccinations depend on the collection of tumor antigens through either physical 
collection or synthetic production. Subsequently the immature DC, typically a 
monocyte or a haematopoietic progenitor cell, is presented with the tumor antigen, 
which is then taken up by the DC through endocytosis. Finally, the DC is then 
introduced to a series of cytokines intended to induce maturation and promote 
expression of cell surface receptors integral to generating a targeted immune 
response. This figure was adopted from source #[27]. 
 
Antigen Selection 
 
 One key element of priming a DC ex-vivo is selecting the type and form of 
antigen to be captured and subsequently presented by the dendritic cell. Antigen 
can be given to the dendritic cell in various forms including whole-purified tumor-
derived proteins, short peptides, cell lysate, tumor-derived RNA, or whole tumor 
cells [28, 29].  The type of antigen delivered to the DCs could have dramatic 
consequences in terms of how quickly the antigen is processed and presented, how 
effective the antigen is at promoting an immune response or even whether or not 
the antigen will induce an immunosuppressive responses that would hinder T-cell 
effectiveness in attacking cancer cells.   
 
Whole Tumor Cell Lysate 
 Whole tumor cell lysate is one of the many types of antigen sources and has 
demonstrated relative success in a number of clinical trials. One example of the use 
of whole tumor cell lysate supernatant as the source of antigen was in a study 
looking at DC vaccinations targeting recurrent ovarian cancer [30]. In this study, six 
patients underwent a series of treatments that began with intravenously 
administered bevacizumab (anti-angiogenic drug) and orally administered 
metronomic cyclophosphamide both of which function to inhibit angiogenesis. The 
metronomic delivery method is one in which the patient receives continuous low-
doses of the drug, (i.e. once a day). This method is favorable in that it has 
demonstrated lower levels of toxicity and it allows the drug to work progressively, 
each administration compounding on the next [31]. Additionally, the lower doses of 
cyclophosphamide have demonstrated preferential depletion of regulatory T cells, 
which can inhibit anti-angiogenic progress. Next, the patients were vaccinated with 
DCs that had been pulsed with autologous tumor cell lysate. Finally, the patients 
were further injected with T-cells that had been previously exposed to the vaccine. 
Out of the six patients treated, four demonstrated anti-tumor immune responses. 
Overall, there was a 50 percent clinical benefit including a remission that lasted 14 
months as well as one complete remission.  While this treatment design 
demonstrates a combinatory approach, it also suggests to a certain extent that DC 
vaccination with tumor lysate as an antigen has the potential to promote anti-tumor 
T-cell immune responses [30].  The researchers in this study discuss several 
manners in which the treatment would be improved upon.  First, the supernatants 
used in this study were derived from “freeze-thawed” tumor lysates; the authors 
suggest that using alternative techniques for obtaining the supernatants may have 
yielded superior results. Secondly, the DCs were not matured with any additional 
stimuli. The researchers also proposed that “stimulation with exogenous cytokines 
and TLR agonists could significantly enhance vaccine potency” [30].   
 
Peptides 
 Another promising category of antigen able to prime DCs is tumor specific 
peptide fragments. These antigens are typically derived from tumor specific 
proteins rather than self-proteins as to avoid an autoimmune response. They can 
also, however promote targeting of over-expressed self-proteins like HER2 for 
breast, PSA for prostate cancer that are expressed on the tumor.  These proteins do 
not activate T-cell responses in-vivo because the tumor cells lack the required co-
stimulatory molecules[3, 29, 30]. One key benefit of using these peptide fragments is 
that they are present in many patients sharing the same kind of cancer, making it 
easier and cheaper to obtain and produce a vaccine that could benefit a large group 
of people. Additionally, the peptide fragments that are associated with tumor 
antigens can be created synthetically and uniformly allowing for a relatively cheap 
means of production compared to using autologous cell lysate, which has to be 
appropriated from each patient individually [32].  In a study performed by Nestle et 
al., DCs were pulsed with several different tumor-derived peptides as well as 
keyhole limpet hemocyanin (KLH), a type of large carrier protein, and delivered to 
patients with melanoma. In this study, the peptide combinations used were tailored 
to the particular patients’ haplotype, thereby maximizing the immune potential. The 
vaccine was injected directly into the lymph nodes. Out of the 16 patients 
participating in the trial, 11 demonstrated delayed-type hypersensitivity (DTH) to 
the peptide pulsed DCs as well as peptide-specific CTL recruitment. Overall, three 
patients manifested partial responses with regression of metastases and two 
patients achieved complete remission [32, 33]. This study highlights several key 
features about antigen selection for DC vaccination. First, an antigen, in this case 
specifically a synthetically produced cancer-related peptide, that produces an strong 
anti-tumor response in one individual, may not be ideal for another patient even one 
with the same diagnosis. Tailoring antigen selection to an individuals’ particular 
haplotype could provide a very valuable and effective treatment tool. This does, 
however, require individualization, which as discussed earlier, can be labor 
intensive and more extensive than a blanket treatment. Second, a combination of 
tumor-associated peptides may be more effective than the use of one sole peptide. 
This method provides the dendritic cell with the opportunity to deliver varied 
antigen and signals to the effector cells thereby creating unique responses and 
optimizing the potential for a successful immune reaction. Additionally, this method 
of ex-vivo DC vaccination demonstrated no indication of autoimmunity or severe 
reactions to the vaccine. This suggests that DC vaccination has the potential to be a 
safe and less toxic form of treatment than chemotherapies and other kinds of cancer 
treatments.  
 Another factor that must be taken into consideration when developing a DC 
vaccination is the type of stimuli that must be added to encourage DC maturation 
and specialization. Thus far, many studies have used a standardized set of cytokines 
including TNF-a, IL-1B, IL-6, which are all pro-inflammatory and PGE2, which is a 
cytokine shown to promote up-regulation of MHC molecules on the DC surface 
molecules. While these cytokines have been successful to a degree at promoting DC 
maturation, it has been suggested that this composition of cytokines fails to induce 
IL-12p70 production and could potentially lead to the production of T-regulatory 
cells. IL-12p70 is a key cytokine produced by DCs involved in encouraging the 
differentiation of naïve T cells into Th1 cells [14]. A variation of this cytokine 
cocktail involves the use of TNF-a, IL-1B, Poly(I:C), IFN-a and IFNy. This blend of 
cytokines has shown to induce the IL-12 production that was lacking from the 
effects of the preceding combination.  
 In a study performed by Stift et al., ten patients diagnosed with medullary 
thyroid carcinoma (MTC) were administered an ex-vivo produced DC vaccination.  
The dendritic cells were matured from peripheral blood monocytes that were 
cultured with GM-CSF, IL-4, TNF-a and IFN-y and tumor lysate antigen.  The 
matured DCs expressed high levels of CD1a, CD11c, CD40, CD80, CD86, CD83 and 
MHC II. This indicates that the DCs were effectively activated to promote T-cell 
activation, differentiation and subsequent anti-tumor potency. In terms of clinical 
effects, seven on the ten patients demonstrated prolonged tumor marker decline. 
Three patients demonstrated a partial objective response, one patient exhibited a 
minor response and two other patients demonstrated stable disease, thus no further 
tumor progression. The researchers propose that TNF-a and IFN-y were critical to 
encouraging the expression of co-stimulatory molecules on the dendritic cells, the 
lack of which can lead to immune-tolerance [34]. The evidence presented in this 
article suggests that the cytokines used in this study could be effective maturation 
inducing agents. It is critical that the DCs not only be matured but also that they 
have the necessary surface molecules to present antigens and to successfully 
activate naive T and B cells through co-stimulation. For an ex-vivo derived 
vaccination to be effective, these conditions along with careful antigen selection and 
presentation must be met.  
 A final key consideration in the production and usage of ex-vivo DC 
vaccination is the site of administration of the matured and primed DCs. So far, part 
of the reason that DC vaccinations have had such limited clinical success is that once 
the DC vaccine has been injected, the vaccine fails to migrate to the secondary 
lymphoid organs[14]. Studies have demonstrated that less than 5% of injected DCs 
typically reach the draining lymph nodes, which is a critical site for cross-
presentation to T-cells [35]. In order to improve the migration of DCs, there are 
several different possible measures that can be taken. First, the DC vaccine could be 
administered at several different sites, thereby maximizing the odds that of 
exposure to T-cells. Second, the DCs could be delivered directly into the lymph 
nodes [14].  
 
In-Vivo DC Vaccination 
 Ex-vivo stimulated DCs have demonstrated immense potential for use in 
antigen-specific immune targeting through vaccination, however, the methods 
employed to produce positive results can be time consuming, labor intensive and 
extremely expensive. As an alternative, many researchers have turned to exploring 
the possibilities of targeting DCs in-vivo. This process eliminates the necessity of 
extracting and culturing autologous DCs, which can only be used for the individual 
from which they were extricated. Additionally, it changes some of the challenges 
that were presented with ex-vivo generation and delivery of the vaccine. For 
example, a main concern with ex-vivo vaccination is the delivery site. The dendritic 
cells must be injected into a location from which they can migrate. In-vivo 
vaccinations, however, depend on the natural migration patterns of DCs from origin 
to presentation of antigen to T and B cells. Under these circumstances, what 
becomes most important is the delivery of the injected antigen to the DCs. Similarly 
it is critical that the maturation cytokines contact the DCs to enable successful 
mediation of antigen specific effector cell responses.  
 In order for an in-vivo DC vaccination to be successful, endogenous DCs must 
be primed to present tumor antigens via both MHC Class I and MHC Class II 
pathways so that both CD4+ and CD8+ T cells are engaged in anti-tumor immune 
responses [14]. As with ex-vivo culturing of dendritic cells, there are several 
different options for antigen sources. Tumor associated antigens can be produced 
from oncogenic viruses such as HPV proteins, overexpressed variants such as 
Her2/neu, which is a oncogene, or self-antigens that are overexpressed specifically 
on tumors [14]. The up-regulation and high expression level of tumor proteins alone 
is an essential defining factor in selecting a self-antigen in order to avoid an auto-
immune response. 
 To enhance the probability of a directed and effective immune response in an 
in-vivo DC vaccination, the chosen antigen must be successfully administered and 
targeted to DCs in vivo. There are several different approaches currently being 
tested to achieve this goal. The first involves the use of soluble mediating proteins 
that interact with DC surface molecules [29]. In this model, the soluble mediators 
are combined with the antigen and subsequently administered to the patient. These 
mediators can play valuable roles in increasing not only the quantity of DCs, but also 
the quantity of antigen that are presented and the migration of the matured DCs. 
Several mediators that can be used to induce DC expansion and maturation in vivo 
include fms-like tyrosine 3 kinase Flt3 ligand (Flt3L) and GM-CSF [29, 36]. These 
mediators can also serve to cause differentiation of the DCs. GM-CSF generates 
CD11b+ and CD8a-. With the addition of Flt3L, however, naïve DCs differentiate in to 
CD11b+CD8a- and CD11b-CD8a+ DCs, each with unique priming and co-stimulatory 
abilities [29].  Heat shock proteins (HSPs), another kind of soluble mediator, can 
bind to DC surface receptors and induce DC maturation and promote presentation of 
antigens via the MHC class I pathway. Cytosine phosphate guanosine 
oligodeoxynucleotide (CpG ODN) is a particularly useful mediator that interacts 
with TLR-9 on DCs and are particularly useful in priming pDCs to stimulate T-cells 
[29, 36].  
 
Particulate Antigen Delivery
 
Figure 3. Representations of 
delivery systems; this figure was adapted from source #
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themselves into particles that can encapsulate antigens [29].  Exposure to VLPs will 
cause DCs to mature and secrete inflammatory cytokines [29, 39]. Additionally, VLP 
can stimulate both CD4+ and CD8+ T cells in vivo. In several ways, VLPs are 
particularly useful in that they act as both a carrier and an adjuvant. A key point to 
acknowledge is that VLP are not infections and are thereby will not adversely affect 
immune or other cells. The Hepatitis B VLP is particularly useful in protecting 
antigen from deterioration. The HB VLP can be taken up by both macrophages and 
DCs, which then present the delivered antigen via the MHC class I pathway. The 
particles that sized in the range of 0.04-0.1 microns were, however, more effectively 
taken up by CD205+DCs, while the larger VLPs were taken up by macrophages [40]. 
PPV-VLPs are taken up exclusively by CD8a- and CD8a+ DCs making them very 
useful in solely targeting these DC subsets in vivo [29].  
 
Synthetic Particles  
 Synthetic nano- and micro-particles are an example of a different type of 
particulate that can be used to deliver antigen to DCs in vivo. In this design, antigens 
can be conjugated to or encapsulated in synthetically created particles that can be 
taken up by CD8a+ DCs and processed both in vivo and in vitro. One key advantage 
to this approach is that there is greater flexibility for antigen selection, more 
uniformity across particles, higher yield and increased stability than with the use of 
VLPs or soluble mediating factors. There are two major categories of synthetic 
particles that can be used; biodegradable and non-degradable.  
 
Biodegradable Particles 
 Biodegradable particles are typically created from hydrolytically degradable 
polyesters such as poly (D,L-lactic-coglycolic acid) copolymers (PLGA), poly  (D,L-
lactide) (PLA), poly (ortho esters) (POE) or from liposomes or ISCOMs. Most of these 
particles are not conjugated with danger signals and therefore do not produce 
strong inflammatory side effects [29]. This makes the particle more tolerable to the 
patients and potentially limiting the detrimental effects of the cancer therapy. PLGA 
is a particular effective particle choice due to the fact that these particles have 
demonstrated the ability to incorporate a wide variety of antigens, which makes 
PLGA particles useful in a wide spectrum of cancers. PLGA particles are able to 
protect the antigen from deterioration and they deliver the antigen to APCs, in 
particular DCs, in a targeted manner. Typically, antigens by themselves have a 
presentation time of approximately 12 hours by dendritic cells. In a study 
performed by Shen et al., it was demonstrated the antigen delivered via PLGA 
particles was effectively presented through the MHC Class I pathway for over 96 
hours. This demonstrates the increased viability and stability of the antigens 
introduced through this particulate system as well as the ability of these particles to 
deliver antigen that targets CD8+ T-cell responses [41]. There is also evidence that 
particulate antigens are more effectively utilized by DCs in cross-presentation and 
activation of T cells [42]. PGLA particles also have the capacity to integrate and 
deliver immune-modulators to DCs, such as TLR ligands, which can both encourage 
DC immune capacity as well as reverse the effects of tumor-induced 
immunosuppression of DCs [42].  Another benefit of using PLGA, is that is has been 
approved by the FDA for the use of several different clinical application including 
drug delivery [43]. This makes it a valuable material in terms of accessibility and 
patient trials.  
 PLA and POE largely incorporate plasmids or tumor DNA as their primary 
antigen. These delivery systems have been shown to be more successful at 
producing antibody, CD4 and CD8 T cell immune responses than when DNA was 
administered without a delivery system. PLA and POE protect the fragile DNA from 
deterioration within the body. These systems, however, have limited antigen 
selection capabilities making them useful only in certain types of cancer [29].  
 Liposomes, another type of antigen delivery system, are small phospholipid 
vesicles that have been regularly utilized in vaccine designs. They, like the other 
particles discussed, are able to encapsulate the selected antigen into their system 
and deliver them to APCs. Liposomes are able to protect the antigens against 
degeneration by the APC and thereby help to prolong the presentation time of the 
antigen. This kind of delivery system helps to facilitate presentation of antigen via 
the MHC class I pathway [29].  
 A fourth and final variety of biodegradable particles are immune-stimulatory 
complexes, also known as ISCOMs. ISCOMs are spherical “cage-like” structures that 
are composed of antigen, saponin, cholesterol and phospholipids [29, 44]. These 
particles are highly immunogenic and are promptly and effectively endocytosed by 
DCs. Delivery of antigen through the ISCOM particles, promote the presentation of 
antigen through the MHC Class II pathway[29]. Studies have shown that ISCOM-
based vaccines are highly effective at stimulating antibody responses in addition to 
facilitating antigen specific CD4+ and CD8+ T cells, including CTL responses.  
Additionally, these vaccines have demonstrated long-lasting immune responses, 
which are critical for enduring tumor eradication [44]. ISCOMS have demonstrated 
greater efficacy when combined with adjuvants such as LPS that contribute to DC 
maturation and thereby the immune response[29]. Functionally, ISCOMS are best 
suited to incorporate recombinant proteins [44].   
 
Non-biodegradable particles 
 Non-biodegradable particles constitute the second kind of antigen delivery 
system that can be created synthetically. Typically, these particles are made from 
latex, gold, silica, iron or polystyrene. These particles are particularly useful in that 
not only can antigen be incorporated on the surface of the structures, but they also 
provide a surface to which adjuvants can be attached. Additionally, due to the non-
biodegradable nature of the particles, they endure inside the body allowing for 
repeated exposure of antigens to DCs and therefore prolonged and recurrent 
immune stimulation [37]. Another advantage of the use of non-biodegradable 
particles is that their synthesis can be highly controlled and their size and shape can 
be manipulated to meet the needs of the vaccine [37, 45]. Non-biodegradable 
particles have demonstrated the ability to be engineered to present antigen highly 
effectively through both MHC class I and class II pathways. These particles represent 
one of the most customizable groups of antigen delivery systems. One of the most 
favorable materials that have been used so far for the construction of non-
degradable particles has been silica. Silica-based nanoparticles (SiNPs) are 
biocompatible, effective at selective tumor targeting and are able to be monitored 
in-vivo real time with multi-modal imaging [45]. Another key aspect of SiNPs is the 
presence the silanol groups on the particle surface. These silanol groups can be used 
to deliver a variety of molecules and adjuvants such as ligands, peptides and 
antibodies. By using the silanol groups, the particles can be modified in ways that 
allow for increased cellular recognition, increased efficacy at being taken up by 
APCs, absorption of biomolecules, and higher ability to be directly targeted to cancer 
cells [45, 46]. These factors that contribute to the effectiveness of the SiNPs as well 
the other benefits discussed relating to non-biodegradable particles as a whole 
demonstrates their potential for being a compelling antigen delivery system for DC 
activation in-vivo. There is, however, some concern that because these particles will 
not degrade naturally in the body, there is the potential for toxicity and 
accumulation of particles within certain tissues [29]. In order to be certain that non-
biodegradable particles are safe for human treatment, these concerns must be 
addressed and tested for optimal dosing and minimal toxic effects.  
 
 
 Figure 4. Antigenic Delivery by Nanoparticle: There are several different methods of 
mediating antigen delivery through nanoparticle delivery. Antigens can be delivered 
through conjugation, where they are chemically attached to the nanoparticle. 
Encapsulation involves delivery of the antigen in which the antigen is enveloped 
within the nanoparticle. Adsorption relies on a charge or hydrophobic interaction 
between the particle and the antigen to connect the two. The final method of 
introducing antigen and nanoparticles together in a vaccine relies simply on mixing 
the two, without any direct interaction of the particle and the antigen [45]. This 
figure was adopted from source [45].  
 
Targeting DC Surface Molecules 
 Up to this point, we have primarily discussed methods of encapsulating or 
securing selected antigens through various particles as a means of delivering it to 
APCs, particularly DCs, in vivo. These methods are utilized to protect the antigen 
from degradation, increase uptake by APCs, prolong antigen presentation time, and 
increase the quantity of the selected antigen directed to DCs. Another aspect of 
delivering antigen to DCs in vivo effectively involves targeting DC receptors 
specifically. Several different adjuvants and antibodies specific to DC surface 
receptors can be introduced either alongside or integrated into antigen delivery 
particles in vaccines to increase their ability to selectively deliver antigen to DCs. 
This is possible through the exploitation of the receptors present on the DC surface; 
antibodies can be modified so that their variable region “fits” the DC receptors 
similarly to how antibodies can selectively bind to antigens. Additionally, the ability 
to target antigen to specific DC receptors consequently allows antigen and antigen 
carriers to be targeted to different DC subsets, thereby tuning immune responses. 
DC targeting can also be used to target antibodies, which instead of providing co-
stimulation with antigen delivery directly, induce signals that aid in DC activation 
and maturation [3].  
 Antigens are largely targeted to DCs through the use of DC surface lectins. 
Many of these receptors belong to the C-type lectin receptor (CLR) family. CLRs 
constitute a group of lectins that share a carbohydrate-recognition domain (CRD), 
which allows them to bind to a select group of sugar residues. This aspect of CLRs is 
valuable in that they can be present on the cell membrane and selectively bind to 
passing sugar groups, connecting them to the DC. Several different CLRs that are 
particularly useful for DC targeting include the mannose receptor, DEC-205 (also 
known as CD-205), and DC-SIGN [36].  
 The mannose receptor is present on immature DCs. Targeting antigen to this 
receptor increases antigen presentation via both the MHC class I and class II 
pathways [36]. The mannose receptor can be targeted in vivo by fusing antigen to an 
anti-mannose receptor monoclonal antibody (anti-MR mAb) [47]. These fused 
complexes have been demonstrated to elicit both CD4+ and CD8+ antigen specific T 
cells. Furthermore, MR targeted antigen vaccination strategies have shown to 
promote anti-tumor responses [47].  
 DEC-205 is another type I CLR that is highly expressed on mature DCs and 
largely functions to facilitate antigen presentation. DEC-205 is expressed in only 
very low levels on other cells making it an ideal candidate for selectively targeting 
DCs.  In terms of research and trials, it is important to note that DEC-205 is 
restricted to CD8+ DCs in mice, but it represented more widely in the human DC 
population. This means that low level responses in the testing of mice, might not 
necessarily reflect the response that would be exhibited in humans. Delivery of 
antigen to DCs through the targeting of the DEC-205 receptor promotes CTL 
responses as well as CD4+ T cells that provide prolonged induction humoral 
immune responses [36].  A key point, however, in the targeting antigen to the DEC-
205 receptor, is that without proper stimulation with additional adjuvants, the DCs 
could induce antigen specific tolerance in lieu of tumor specific immune responses 
[48].  In order to avoid anergic responses, the antibody targeting DEC 205 (α-DEC-
205 Ab) should be administered in conjunction with adjuvants that induce DC 
activation such as TLR3, TLR7 or CD40 agonists [48].   
 DC-SIGN is a surface receptor that is primarily expressed on immature 
dendritic cells, and at lower levels on mature DCs. The antibody targeting the DC-
SIGN receptor effectively locates DCs that are present in the draining lymph nodes, 
which is an ideal site for DC activation, stimulation and subsequent presentation of 
antigen to the naïve T cells that settle in the lymph nodes [36]. This method of 
targeting antigen to DCs has demonstrated that the presentation of antigen through 
both MHC class I and II molecules and promotes memory T-cell, CD4+ T-cell, CD8+ T 
cell as well as humoral responses leading to a multi-faceted and antigen specific 
immune response. Currently, there is a clinical trial in progress examining the 
effects of a DC-SIGN-targeted vaccine based upon the use as of a modified lentiviral 
vector. Thus far, the use of the lentiviral vector in conjunction with the DC-SIGN-
targeting approach has been shown to initiate aggressive anti-tumor T cell 
responses [49].  
 
SPAS-1 Conjugated Micro-particle Project 
 Several different methods have been described throughout this article as 
possible ways to initiate and enhance immune responses against cancer cells 
through the exploitation of dendritic cells’ natural abilities as antigen presenting 
cells. Overall, the methods discussed have been designed to introduce dendritic cells 
to a selected cancer-specific antigen and subsequently induce the presentation of 
these antigens to immune effector cells. In order to further explore the potential and 
efficacy of some of the approaches designed, we decided to test a possible 
vaccination strategy utilizing iron micro-beads as a non-biodegradable antigen 
carrier, SPAS-1 as the antigen, and several different adjuvants to promote DC 
maturation and activation. The processes used to create these particles along with 
tests performed to evaluate the ability of the micro-particles to affect DCs will be 
detailed and assessed in the following sections.  
 SPAS-1 is a protein produced by the murine prostate cancer cell line TRAMP-
C1. SPAS-1 is a useful target for cancer therapy because it can be recognized by a 
subset of tumor-specific CD8 T cells, it is upregulated by prostate cancer cells during 
tumorigenesis and it is not expressed on normal cells. This means that SPAS-1 can 
be targeted effectively by the immune system and that it will not promote 
autoimmune immune responses. In order to elicit an immune response against the 
SPAS-1 antigen, we examined the effects of using a micro-particle vaccine containing 
the SPAS-1 antigen combined with lipopolysaccharide (LPS), CL264, and αDEC-205. 
Lipopolysaccharide (LPS) is a molecule found on the outer membrane of some 
bacteria. It is a one of the pathogen associated molecular patterns (PAMPs) that can 
be recognized by immune cells with pattern recognition receptors (PRRs). When 
encountered by macrophages, dendritic cells or some B-cells it elicits a strong 
immune response encouraging these cells to secrete pro-inflammatory cytokines. 
CL264 (in this case biotin labeled) is a ligand that promotes dendritic cells to secrete 
the pro-inflammatory molecule interferon-alpha (IFN-α) and to activate the NF-κB 
pathway. NF-κB is a protein that is critical in regulating genes and up-regulating 
genes that are involved in T-cell development, maturation and proliferation. These 
proteins are able to activate immune cells to respond to the presence of the tumor. 
αDEC-205, the antibody that binds to DEC-205, was used as the DC targeting 
antibody.  
 The micro-particles were created and tested for efficacy through 
administration to DCs in-vitro, however, the end goal of this particle was in vivo 
antigen delivery to and subsequent activation of DCs in order to prime tumor Ag-
specific CD8 T cells.  
 
SPAS-1 Purification 
 The first step in the process of creating the micro-particle was to obtain a 
purified version of the SPAS-1 protein that could be used as an effective antigen. In 
this study, the SPAS-1 protein was derived from a 6xhistag-GFP-(green florescent 
protein) tagged SPAS-1 recombinant E. coli. To separate the GFP-tagged SPAS-1 
from the E.coli, the recombinant specimen was subjected to a series of buffer 
combinations aimed at solubilizing the SPAS-1 protein, thereby separating it from 
the E. coli. The most effective buffer cocktail consisted 100µL base solution (10mM 
Imidazole, 50mM Sodium Phosphate, 5mM arginine and 0.01% tween 20 in 200mL 
distilled water), 125µL 2M Urea, 125µL 750mM NaCl, and 25µL 0.1% Triton. The 
solubilizing solutions were evaluated for their ability to separate the soluble from 
the insoluble portions of the recombinant E. coli. Due to the fact that the 
recombinant E. coli was GFP-tagged, the relative fluorescent intensities of both the 
soluble as well as the insoluble portions were able to be determined through the 
examination of the portions using a using a 510-590 wavelength filter. The soluble 
to insoluble fraction ratio was determined using the fluorescent intensities for each 
buffer solution. The buffer solution that produced the highest yield of the soluble 
portion (i.e. the SPAS-1) relative to the insoluble portion was selected as the most 
effective buffer solution.  
 In order to continue purifying the remaining SPAS-1 recombinant E. coli, the 
recombinant E. coli was subjected to the optimal solubilizing solution. The mixture 
was then run through a centrifuge, separating the soluble and insoluble fractions. 
Next off, the soluble fraction was filtered through a three filter series of 1.2µ, 0.45µ 
and 0.2µ filters. This process resulted in approximately a 50% SPAS-1 protein 
extraction efficiency when compared to the amount of SPAS-1 present in the 
original recombinant solution.  
 The filtered solubilized SPAS-1 solution was then further purified from 
background materials that were not removed through the preliminary extraction of 
the SPAS-1 protein from the SPAS-1 recombinant E. coli. This was achieved by using 
the “Akta Pure” which uses the Nickel affinity purification process. First the SPAS-1 
protein solution was run through the purification column. This was followed by a 
load binding/ wash buffer consisting of 10mM Imidazole, 50mM Sodium Phosphate, 
5mM Arginine, 2M Urea, 0.01% Tween-20, 2M Urea and 0.1% Triton x-100 in 
ddH2O. This wash buffer was used to wash away anything that was not sticking to 
the nickel column. After this, an elution buffer (made of 250mM Imidazole, 50mM 
Sodium Phosphate, 1.5M Sodium Chloride and 5mM Arginine in ddH2O and 0.5M 
NaOH) was run through the column and the flow-through was collected. The elution 
buffer functions to strip the column of the target SPAS-1 protein. Next, the elution 
buffer was run through once again. A slightly altered version of the elution buffer 
was then run through the column, in which the concentration of Imidazole was 
increased to 500mM and concentration of Sodium Chloride was increased to 2M. 
These runs were followed by another wash flow-through, an elution flow through, a 
NaCL flow through and finally a Nickel solution flow through. The collected flow 
through samples were then examined for their levels of fluorescence.  
 
Figure 5. Average MFI of Products of SPAS-1 Purification Process 
 
 The collected samples and their respective mean fluorescent intensities 
(MFIs) demonstrated that the flow through from the primary elution yielded the 
highest level of purified SPAS-1. The results demonstrated that the Elution #1 
yielded the highest concentration of the SPAS-1 protein. This elution, along with the 
third elution run through were subsequently concentrated for use in the following 
experiment.  
 In order to examine the progression of the purification throughout the 
varying purification steps and to estimate the final yield of the SPAS-1 protein, the 
solutions present through the various stages of protein purification were run 
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through the Thermal Cycler and subsequently added into nine different wells of the 
gel for a SDS-PAGE (sodium
test. In order to be able to examine the results, dye was added to stain the proteins 
present in the gel and the gel was imaged. 
purification were added to the wells in their respective orders: 1) insoluble SPAS
Recombinant E. Coli 2) Soluble SPAS
Protein 4) Purification Binding Flow
6) Elution #1 7) Elution #3 8) Concentrated Elution #1 9) Concentration Elution #3. 
 
 
 
 
 
 
 
 
 
Figure 6. 3-D Representation of SDS
purification process 
 
 In well number two, we can see that the original insoluble SPAS
recombinant E. coli has a large amount of many different proteins in it. As the 
purification process progresses, the amount and variation of the proteins decr
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until we are left primarily with our target protein, which is shown in the
sample which was a concentrated version of elution #1. It was surprising to see that 
the concentrated elution 1 was very similar to the well number four which 
represents the filtered solub
purification process was not as successful as we might have hoped. This gel does 
however show us the yield of the SPAS
1 represents the standards column f
determined. We compared the amount of SPAS
well 1 and we can see that we have approximately 500ng of the protein in 20µL
~25ng/µL) of the concentrated elution solution #1. 
 
 
 
 
 
 
Figure 7. Overall SPAS-1 Purification Process 
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 Micro-Particle Production 
 Next, we created a variety of micro-particles and determined the relative 
amount of antigen and antibody bound to the micro-bead. Iron-oxide micro-beads 
with streptavidin were used as a form of non-biodegradable antigen carrying micro-
particle. We used a tumor-specific antigen (SPAS-1) plus LPS, CL264 and αDEC-205. 
The combination all the adjuvants on a micro-bead creates what are called dendritic 
cell activating receptor-targeted particles (or DARTs). The iron-oxide micro-beads 
were covered in streptavidin molecules. Streptavidin has an extremely high affinity 
for biotin.  In order to determine the most effective micro-particle we created five 
different variations. The variations were as follows: 1) iron-oxide beads + LPS, 2) 
beads + CL264, 3) beads + αDEC-204, 4) beads + SPAS-1, 5) DARTS + SPAS-1.  
 In order to connect the αDEC-205 to the micro-bead, we had to add an anti-
rat secondary antibody with a biotin molecule that could bind to the bead. Because 
the αDEC-205 used in this experiment is a rat antibody it connects to the anti-rat 
secondary antibody. The SPAS-1 requires an additional step. First, an anti-rabbit 
secondary antibody, which has a biotin molecule, connects to the streptavidin 
molecule. Second, an anti-6x-histag of rabbit origin connects to the secondary 
antibody. Third, because the SPAS-1 antigen was created with a 6x-poly-histidine 
tag, it can be added and connect to the anti-6x-histag. 
 
. 
Figure 8. Example of Micro
SPAS-1 micro-particle arrangement in which all of the adjuvants as well as the SPAS
1 antigen have been conjugated to the iron
streptavidin molecule and a series of binding antibodies.  
 
Figure 9. Image of DC2.4 Dendritic Cells with DARTs + SPAS
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 Because the αDEC-205 and SPAS-1 antigen contain a fluorescent tag, the 
amount retained on the micro-particle can be tracked. Known amounts of αDEC-205 
antibody and SPAS-1 antigen were added to the micro-particle. After washing, the 
particles the amount of SPAS-1 and αDEC-205 that were retained on the micro-
particles was determined. For the beads + αDEC-205, approximately 11% was 
retained after the wash. For the DARTS and the added αDEC-205 only 4% was 
retained. There were approximately 22,000 αDEC-205 molecules on the beads + 
αDEC-205 microparticle and only 8,000 on the DARTS + SPAS-1 molecule. This is 
likely due to the competition for space on the DARTS particle. On the DARTS there is 
not only αDEC-205 but LPS and CL264 as well. On just the beads, the SPAS-1 antigen 
was retained at 17.1% after the wash and on the DARTS 16.8% remained attached. 
We determined that there were approximately 25,000 SPAS-1 molecules per iron-
oxide micro-bead for both the beads + SPAS-1 micro particle as well as the DARTS + 
SPAS-1 molecule. These higher numbers indicate strong bonds allowing the SPAS-1 
to securely attach to the micro-particle.  
 
 Figure 10. Mean Fluorescent Intensity of αDEC-205 before and after wash                                                          
 
 
Figure 11. Mean Fluorescent Intensity of SPAS-1 on Beads before and after wash. 
 
Figures 11 and 12. Figure 10 depicts the mean fluorescent intensity of 12 wells of 
the αDEC-205 before and after wash per condition. Figure 11 depicts the mean 
fluorescent intensity of 12 wells of SPAS-1 per eight conditions shown above.  
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Micro-particle Testing 
 
 In order to determine the relative effectiveness of the engineered micro-
particles, several different tests were performed to examine the ability of the micro-
particles to be taken up and processed by DC2.4 dendritic cells and thus induce an 
immune response. The first test performed was an immunocytochemical test, which 
was used to assess the expression of CD40, CD86, MHC Class I and MHC Class II 
molecules on dendritic cells after exposure to the different micro-particles. The 
dendritic cells exposed to the micro-particles were incubated with fluorescently 
tagged anti-CD40, anti-CD86 and anti-MHC Class I/II antibodies. (Approximately ## 
hours or min later), the dendritic cells were scanned to determine the expression of 
the indicated surface molecules.  
 
 
 
 
Figure 12. Fluorescence of Treated Dendritic Cell: Columns 1
with nothing. Columns #4-
expression. DC2.4 cells were treated with
beads + LPS, D) Beads + CL264
SPAS-1. 
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over baseline expression, CD86 was increased over 40%, MHC class I expression 
increased over 30% and MHC class II expression increased by over 200% over the 
baseline expression in untreated dendritic cells. All of the treatments besides the 
beads only treatment demonstrated increased levels of surface receptors. However, 
we observed significant experimental variation, thus these data need to be repeated 
to ensure the results are consistent. We believe that much of this error is a result of 
the timeframe in which the experiment was done. The expression levels were read 
approximately 24 hours after the dendritic cells were exposed to the micro-
particles. It is possible that had the cells been able to incubate longer with the 
particles, there may have been less error in the readings and a more accurate 
representation of the levels surface receptor expression.   
 The next test performed was an enzyme-linked immunosorbent assay 
(ELISA)  that was used to test for production of the cytokines TNF-alpha and IL-6. 
The ELISA was performed as dictated by the eBioscience ELISA kit.  
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Figure 13. Concentration of IL-6 Secreted by Dendritic Cells after Treatment: Mean 
concentration of IL-6 secretion of eight wells per treatment.  
 
Figure 14. Concentration of IL-6 Secreted By Dendritic Cells After Treatment: Mean 
concentration of TNF-α secretion of eight wells per treatment.  
  
 In the previous experiment, we were looking at the surface receptors being 
expressed by dendritic cells after exposure to the micro-particles described in 
experiment 5. In this experiment, we are looking at what cytokines the dendritic 
cells secrete to determine how these treatments affect DC polarization. To do this 
we looked at two cytokines, IL-6 and TNF-α. IL-6 is a cytokine that is involved in 
promoting inflammation and in the maturation and differentiation of B cells. Tumor 
Necrosis Factor Alpha (TNF-α) is an inflammatory cytokine involved in tumor 
necrosis, inhibition of tumorigenesis, neutrophil proliferation and apoptosis. The 
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increased production of these cytokines by a dendritic cell indicates that the 
dendritic cell has recognized a potential threat and is promoting an immune 
response against that threat.  
 We established baseline levels of IL-6 and TNF-α being produced by 
dendritic cells. These dendritic cells produce an average of 0.33ng/mL of IL-6 and 
0.35ng/mL TNF-α. The IL-6 ELISA shows that dendritic cells exposed to beads + 
LPS, beads + DEC-205 demonstrate a slight increase, while the cells exposed to 
beads + SPAS-1 and DARTS + SPAS-1 secrete over 9 times the amount of IL-6 than 
the untreated cells. This suggests that while LPS and DEC-205 can influence a 
dendritic to secrete IL-6, exposure to a specific antigen drives a more extreme 
response. Furthermore, the combination of the antigen with the DARTS complex 
drives an even slightly higher concentration of IL-6. This suggests that the 
combination of antigens and adjuvants is the most successful at encouraging 
dendritic cells to secrete IL-6.  
 In the TNF-α ELISA, the beads + LPS, beads + SPAS-1 and DARTS + SPAS-1 all 
show highly increase concentrations of TNF-α. The LPS treatment results in a TNF-α 
concentration of 1.46ng/mL, the beads + SPAS-1 treatment a concentration of 
2.27ng/mL and the DARTs + SPAS-1 treatment a concentration of 2.38ng/mL. The 
beads + CL264 treatments shows a small increase while the beads only and beads + 
DEC-205 treatments have almost no effect on TNF-α secretion. These results 
suggest that the LPS, which has a pathogen-associated molecular pattern, and the 
SPAS-1 antigen have the most effect on the dendritic cells, the combination of which 
drives the highest response and thus the highest concentration of secreted TNF-α.   
Conclusions 
 Overall this project has illustrated several key promising features of 
dendritic cell vaccinations and it has also identified several areas that could be 
improved upon and re-worked for stronger anti-tumor immune responses.  
When exposed to the micro-particles, the beads + LPS micro-particles demonstrated 
the highest level of up-regulation of cell surface receptors including CD86, CD40, 
MHC Class I and MHC Class II molecules. The DARTs + SPAS-1 micro-particle only 
demonstrated up-regulation of CD86 and MHC Class II molecules over the baseline. 
As discussed previously, it is possible that a prolonged incubation period could lead 
to different results, however the results do indicate interesting aspects of dendritic 
cell activation. First, LPS is a PAMP, which was used in this experiment to instigate a 
strong immune response in the dendritic cells. It is evident that this was true in the 
case of the up-regulation of cell-surface receptors. It is interesting that there was 
significantly less prevalence of the surface receptors when the dendritic cells were 
exposed to the DARTs + SPAS-1 micro-particle. This indicates that due to the 
competition for space on the micro-bead, less LPS was attached to the micro-particle 
and therefore we did not see as strong of response. Additionally, it indicates that the 
SPAS-1 antigen had little to no effect on inducing an up-regulation in surface 
receptors on the DCs.  
 While the cell surface receptors were not highly impacted by the DARTs+ 
SPAS-1 micro-particles, the cytokine production demonstrated significantly higher 
levels of secretion by dendritic cells that were exposed to the beads + SPAS-1, and 
even more so by the DARTs+SPAS-1 micro-particles. These results indicate that the 
SPAS-1 antigen plays a crucial role in promoting cytokine secretion by the DCs. 
Additionally, the results show that the addition of the adjuvants further promote 
this function.  
 While this was just one study used to examine the effects of antigen and 
adjuvants through a micro-bead delivery system on dendritic cell function, there are 
several different things that could be improved upon in subsequent testing. First, 
while the purification process was relatively effective in singling out the SPAS-1 
antigen, as can be seen in Figure 6, there are still other proteins present in the 
solubilized solution that was created. A purer form of SPAS-1 may result in better 
results and stronger DC responses. Furthermore, as described in previous sections, 
the use of non-biodegradable antigen delivery systems has several benefits, but 
these particles also have the potential to have toxic side effects, build up in the 
tissues as well as limited re-vaccination potential. The use of a biodegradable 
antigen carrier such as a PLGA or ISCOM micro-particle could have the same 
immunogenic effects without some of the concerns relating to non-biodegradable 
systems.  Finally, it may also be beneficial to tinker with different combinations of 
adjuvants in order to determine the optimal combination for maturing DCs, 
increasing DC surface receptor expression and promoting cytokine secretion, all of 
which are crucial to antigen presentation, T-cell activation and differentiation and 
an overall stronger anti-tumor immune response.  
 
 
 
Summary  
 Cancer therapy has taken considerable strides in the past years. The 
introduction of immunotherapy as a viable form of cancer treatment has provided a 
new platform for growth, innovation and a powerful tool for fighting cancers by 
harnessing the innate prowess of the immune system. One area of advancement in 
the immunotherapy originates from the ability to enhance the immune system’s 
natural abilities with the addition of adjuvants and stimuli through vaccination.  In 
this study, we sought to explore the immunogenic potential of vaccination of both 
ex-vivo primed dendritic cells as well as vaccinations aimed at targeting and 
activating dendritic cells in-vivo.  
 Several different factors have been discussed in the examination of dendritic 
cell vaccinations. These factors include ex-vivo versus in-vivo targeting of dendritic 
cells, antigen selection, adjuvant selecting, antigen-carrier options and DC targeting 
strategies. In order to create an effective vaccine that can stimulate a lasting and 
targeted anti-tumor response, all of the components of a vaccination must be 
considered not only for their ability to function collaboratively, but also to work for 
the individual cancer scenario. Effectively, this means that there is not one perfect 
cure all for cancer, however, there is the potential for different vaccines to work 
productively for particular cancers and at different stages of cancer progression.  
 The individual project presented in this article addresses some of the factors 
that can contribute to the success of a dendritic cell-based vaccination strategy. The 
adjuvants selected for vaccination can play unique and critical roles in priming 
dendritic cells for antigen presentation and subsequent T-cell activation and 
differentiation. In the current project, the adjuvants I selected played a crucial role 
in promoting dendritic cells to produce surface cell receptors critical to antigen 
presentation and co-stimulation of T-cells. In contrast, the specific antigen selected 
had much less of an impact on cell surface receptors, but still had a tremendous 
effect on inducing cytokine secretion by the DCs. These unique functions of the 
adjuvants and antigen demonstrate their interdependence and the importance of 
creating a balanced vaccine that contributes sufficiently to both aspects of DC 
activation and functionality.  
 Overall, vaccinations aimed at inducing dendritic cell responses that have the 
ability to direct targeted, tumor specific immune attacks, have the potential to 
become not just one type of cancer therapy, but one of the most effective and non-
toxic cancer eradication methods. Dendritic cell vaccinations are customizable, 
workable and largely innocuous. These vaccinations are geared at wielding the pre-
existent defense mechanisms and functions of the immune system and enabling 
them to recognize cancer cells as malignancies. In addition to a prompt immune 
response, vaccinations have the potential to induce lasting immunity, which serves 
to prevent recurrent tumor growth. With further refinement and testing, 
immunotherapy through vaccination has the capacity to become a powerful tool in 
cancer therapy.   
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